2017. ID:2043 Response to a 2-Indolinones laboratory based regimen analogous in cancerous-infected cells. Biomedical Research and Therapy. 4, S (Sep. 2017), S74-S75. DOI:https://doi.org/10.15419/bmrat.v4iS.280.